Search results
Results from the WOW.Com Content Network
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, is a subunit COVID-19 vaccine candidate developed by Novavax and the Coalition for Epidemic Preparedness Innovations. [661] [662] Full (4) Australia [663] Canada [664] [665] Japan [666] South Korea [667]
Credit - Catherine Falls Commercial—Getty Images. I n 1978, a team of Harvard Medical School researchers examined whether people with lupus responded to the influenza vaccine differently from ...
Acuitas Therapeutics Inc. is a Canadian biotechnology company based in Vancouver, British Columbia.The company was established in February 2009 to specialize in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticle (LNP) technology, a key component of the mRNA vaccines deployed for COVID-19.
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA).
The Sanofi–GSK COVID-19 vaccine, sold under the brand name VidPrevtyn Beta, is a COVID-19 vaccine developed by Sanofi Pasteur and GSK. [ 4 ] [ 5 ] The Sanofi–GSK COVID‑19 vaccine was approved for medical use in the European Union in November 2022.
In August, China's National Intellectual Property Administration issued the country's first COVID-19 vaccine patent to CanSino. [34] On 16 May 2020, Canadian Prime Minister Justin Trudeau announced Health Canada had approved Phase II trials to be conducted by the Canadian Center for Vaccinology (CCfV) on the COVID-19 vaccine produced by CanSino.
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield [31] and Vaxzevria [1] [32] among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca , [ 33 ] [ 34 ] [ 35 ] using as a vector the modified ...
While mRNA vaccines, such as the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of +90%, mRNA vaccines present distribution challenges for some nations, as some may require deep-freeze facilities and trucks. By contrast, the BIBP vaccine can be transported and stored at normal refrigeration temperatures. [17]